Zacks Research Has Positive Outlook for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $0.58 for the quarter, up from their previous forecast of $0.57. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ FY2025 earnings at $2.41 EPS, Q2 2026 earnings at $0.70 EPS and Q4 2026 earnings at $0.70 EPS.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

A number of other brokerages also recently weighed in on EW. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Down 1.5 %

Shares of NYSE:EW opened at $71.79 on Thursday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $72.36 and a 200 day simple moving average of $70.36. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market cap of $42.34 billion, a P/E ratio of 10.30, a P/E/G ratio of 4.82 and a beta of 1.10.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the sale, the chief financial officer now owns 30,387 shares of the company’s stock, valued at approximately $2,150,791.86. The trade was a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock valued at $2,799,104 in the last 90 days. 1.29% of the stock is currently owned by company insiders.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Harbor Capital Advisors Inc. lifted its holdings in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB increased its stake in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its stake in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $4,845,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.